Emergent BioSolutions (EBS) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/13/2026
- S&P 500, Nasdaq decline as Iran tensions jolt sentiment; chip stocks fall
- SK Hynix’s record plunge drags down global chip stocks
- Oil gains over 4% as Trump says US reinstating Iran naval blockade
- Ditching streaming could boost Disney stock by 40%, Wells Fargo says
- AstraZeneca stock dips as HSBC downgrades stock on 'tough path ahead'
- Former emir of Qatar, Sheikh Hamad bin Khalifa Al Thani, dies at 74
- Goldman Sachs Upgrades NIO (NIO) to Buy
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- S&P 500, Nasdaq decline as Iran tensions jolt sentiment; chip stocks fall
- Japan has no plans to overhaul pension funds' asset allocation, sources say
Emergent BioSolutions Reports Financial Results for First Quarter 2020
April 30, 2020 4:09 PM EDTReaffirms full year 2020 financial forecast
Executes multi-faceted response to COVID-19 drawing upon longstanding investments in capabilities to address public health threats, as well as expertise in vaccines, therapeutics, and contract development and manufacturing
GAITHERSBURG, Md., April 30, 2020 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) reported financial results for the three months ended March 31, 2020.
"Emergent is uniquely positioned to respond to the unprecedented challenges of the COVID-19 pandemic," said Robert G. Kramer Sr., president and chief executive officer of Emergent BioSolutions. We are deploying our decades of experience in vaccines and... More
